
A Cancer-Specific Anti-Podoplanin Monoclonal Antibody, PMab-117-mG2a Exerted Antitumor Activities in Human Tumor Xenograft Models

[Tomohiro Tanaka](#) , [Hiroyuki Suzuki](#) ^{*} , [Tomokazu Ohishi](#) , Mika K. Kaneko , [Yukinari Kato](#) ^{*}

Posted Date: 7 October 2024

doi: 10.20944/preprints202410.0464.v1

Keywords: cancer-specific monoclonal antibody; podoplanin; ADCC, mouse xenograft model



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

Article

A Cancer-Specific anti-Podoplanin Monoclonal Antibody, PMab-117-mG_{2a} Exerted Antitumor Activities in Human Tumor Xenograft Models

Tomohiro Tanaka ¹, Hiroyuki Suzuki ^{1,*}, Tomokazu Ohishi ^{2,3}, Mika K. Kaneko ¹ and Yukinari Kato ^{1,*}

¹ Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryō-machi, Aoba-ku, Sendai, Miyagi 980-8575, Japan

² Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, 18-24 Miyamoto, Numazu-shi, Shizuoka 410-0301, Japan

³ Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, 3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141-0021, Japan

* Correspondence: hiroyuki.suzuki.b4@tohoku.ac.jp (H. S.); yukinari.kato.e6@tohoku.ac.jp (Y. K.); Tel.: +81-22-717-8207 (H. S. and Y. K.)

Abstract: Podoplanin (PDPN) overexpression is associated with poor clinical outcomes in various tumors. PDPN is involved in tumor malignant progression by promoting invasiveness and metastasis. Therefore, PDPN is considered a promising target of monoclonal antibody (mAb)-based therapy. Because PDPN also plays an essential role in normal cells such as kidney podocytes, cancer specificity is required to reduce adverse effects on normal cells. We developed cancer-specific mAbs (CasMabs) against PDPN, PMab-117 (rat IgM, kappa), by immunizing rats with PDPN-overexpressed glioblastoma cells. The recombinant mouse IgG_{2a}-type PMab-117 (PMab-117-mG_{2a}) reacted with the PDPN-positive tumor PC-10 and LN319 cells but not with PDPN-knockout LN319 cells in flow cytometry. PMab-117-mG_{2a} did not react with normal kidney podocytes and normal epithelial cells from the lung bronchus, mammary gland, and corneal. In contrast, one of the non-CasMabs against PDPN, NZ-1, showed high reactivity to PDPN in both tumor and normal cells. Moreover, PMab-117-mG_{2a} exerted antibody-dependent cellular cytotoxicity in the presence of effector splenocytes. In the human tumor xenograft models, PMab-117-mG_{2a} exhibited potent antitumor effects. These results indicated that PMab-117-mG_{2a} could be applied to antibody-based therapy against PDPN-expressing human tumors while reducing the adverse effects.

Keywords: cancer-specific monoclonal antibody; podoplanin; ADCC; mouse xenograft model

1. Introduction

Since the first monoclonal antibody (mAb) was approved by the U.S. Food and Drug Administration (FDA) in 1986, a variety of therapeutic antibodies and their derivatives have been developed together with advances in antibody engineering [1,2]. In mAb therapy for solid tumors, trastuzumab and pertuzumab were approved by the FDA for human epidermal growth factor receptor 2 (HER2)-overexpressed breast cancer in 1998 and 2012, respectively [3]. An anti-epidermal growth factor receptor (EGFR) mAb, cetuximab was approved by the FDA for metastatic colorectal cancer in 2004 and head and neck squamous cell carcinomas (HNSCCs) in 2006 [4]. These mAbs exerted antibody-dependent cellular cytotoxicity (ADCC) and have been used in monotherapy or combination therapy with chemotherapy [5].

Although the number of naked mAb targets for solid tumors has not increased, antibody-drug conjugates (ADCs) are one of the fastest-growing formats of mAb-based solid tumor therapy [6]. ADCs possess covalently-bound cytotoxic agents (payloads) via synthetic linkers, which exhibit high stability and selectivity and favor pharmacokinetics [7]. In solid tumor therapy, trastuzumab emtansine (T-DM1) was first approved by the FDA in 2013 [8]. Since 2013, more than 60 ADCs entered clinical trials for a wide range of tumors. Enfortumab vedotin (target: Nectin-4) [9], Sacituzumab

govitecan (target: TROP2) [10], Trastuzumab deruxtecan (target: HER2) [11], Tisotumab vedotin (target: Tissue factor) [12], and Mirvetuximab soravtansine (target: Folate receptor alpha) [13] were approved by the FDA. However, toxicity remains an essential problem in the development. Among 97 ADCs that have entered clinical trials since 2000, 81 trials (84%) were terminated. Causes of termination were disclosed for 79. The reason for the discontinuation was a lack of efficacy (32 agents) and safety issues (32 agents) [6]. On-target, off-tumor toxicity is a cause of adverse effects when the target antigen is expressed in normal cells. Therefore, a better understanding and management of the tumor specificity of mAbs will be essential for further optimization.

Podoplanin (PDPN)/T1 α /gp36/Aggrus is a type I transmembrane glycoprotein that contains three platelet aggregation-stimulating domains called PLAG1, PLAG2, and PLAG3 [14]. Some PLAG-like domains (PLDs) also exist, one of which is called the PLAG4 [14]. The PLAG3 and PLAG4 are modified with *O*-glycosylation, which is essential to bind to C-type lectin-like receptor 2 (CLEC-2) and PDPN-induced platelet aggregation [15,16]. The PDPN-induced platelet aggregation plays critical roles in tumor cell survival in circulation and hematogenous metastasis through the evasion from antitumor immunity [17] and promotion of embolization [18,19].

PDPN promotes tumor metastasis through the recruitment of the ezrin, radixin, and moesin (ERM) complex, which remodels actin cytoskeletons and regulates epithelial-to-mesenchymal transition (EMT) [20]. The depletion of PDPN potently suppressed transforming growth factor- β (TGF- β)-induced EMT [21], indicating the critical roles of PDPN in EMT and malignant progression of tumors. Moreover, PDPN-positive tumor cells exhibit the diverse pattern of invasion, such as ameboid invasion in melanoma [22] and collective invasion in SCCs [23]. Furthermore, PDPN binds to hyaluronan receptor CD44 [24] and matrix metalloproteinases [25]. The complexes mediate the formation of tumor invadopodia, which promotes extracellular matrix (ECM) degradation and invasiveness [26]. In the clinic, high PDPN expression was associated with shortened overall survival in patients with various tumors, including HNSCCs, esophageal SCCs, gastric adenocarcinomas, gliomas, and mesotheliomas [27-30].

The elevated expression of PDPN is also observed in cancer-associated fibroblasts (CAFs), a main constituent of the tumor microenvironment (TME). Increased abundance of PDPN in CAFs is correlated with poor clinical outcomes in pancreatic [31], breast [32], and lung [33-35] cancer patients. The PDPN-positive CAFs from lung tumors were reported to affect the therapeutic outcomes of EGFR inhibitors [36]. The PDPN-positive CAFs are also involved in the formation of an immunosuppressive TME through the secretion of TGF- β , which reduces antitumor immune responses [37]. Additionally, PDPN-positive CAFs were associated with low interleukin-2 activity and trastuzumab resistance in patients with HER2-positive breast cancer [38]. Therefore, PDPN in tumors and CAFs has been recognized as a useful diagnostic marker and an attractive target for tumor therapy. Since PDPN plays an essential role in normal cells such as kidney podocytes, lymphatic endothelial cells, and lung alveolar epithelial type I cells, anti-PDPN mAbs that recognize tumor cell-expressed PDPN but not normal cell-expressed PDPN have been desired for tumor therapy.

Our group has developed cancer-specific mAbs (CasMabs) against PDPN, which were obtained by immunization of mice with PDPN-overexpressed glioblastoma LN229 cells. LpMab-2 [39] and LpMab-23 [40] were selected by the cancer-specific reactivity in flow cytometry and immunohistochemistry. Furthermore, they are converted and produced mouse IgG_{2a} type mAbs and showed the potent ADCC and antitumor effect in xenograft models of human tumors [41,42]. In this study, we established another CasMab against PDPN (PMab-117) by immunization of a rat with PDPN-overexpressed glioblastoma LN229 cells. We further evaluated the ADCC activity and antitumor effect against PDPN-positive tumor cells.

2. Materials and Methods

2.1. Cell Lines and Cell Culture

LN229, HBEC3-KT, hTERT-HME1, and P3X63Ag8U.1 (P3U1) were purchased from the American Type Culture Collection (ATCC, Manassas, VA). 293FT was purchased from Thermo Fisher Scientific, Inc. (Thermo; Waltham, MA, USA). PODO/TERT256 and hTCEpi were purchased from EVERCYTE (Vienna, Austria). Human glioblastoma LN319 cells were purchased from Addexbio Technologies (San Diego, CA, USA). Human lung squamous cell carcinoma PC-10 cells were purchased from Immuno-Biological Laboratories Co., Ltd. (Gunma, Japan).

PDPN-overexpressed LN229 (LN229/PDPN) cells were established as previously described [39]. LN229, LN229/PDPN, and LN319 cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM) [Nacalai Tesque, Inc. (Nacalai), Kyoto, Japan]. PC-10 cells were cultured in Roswell Park Memorial Institute (RPMI)-1640 medium (Nacalai). These media were supplemented with 10% heat-inactivated fetal bovine serum (FBS; Thermo), 0.25 $\mu\text{g}/\text{mL}$ amphotericin B, 100 $\mu\text{g}/\text{mL}$ streptomycin, and 100 units/mL penicillin (Nacalai). ExpiCHO-S and Fut8-deficient ExpiCHO-S (BINDS-09) cells were cultured as described previously [41].

Immortalized normal epithelial cell lines were maintained, as follows; PODO/TERT256, MCDB131 (Pan Biotech, Bayern, Germany) supplemented with GlutaMAXTM-I (Thermo), Bovine Brain Extract (9.6 $\mu\text{g}/\text{mL}$, Lonza, Basel, Switzerland), EGF [8 ng/ml, Sigma-Aldrich Corp. (Sigma), St. Louis, MO, USA], Hydrocortisone (20 ng/mL, Sigma), 20% FBS (Sigma), and G418 (100 $\mu\text{g}/\text{mL}$, InvivoGen, San Diego, CA); HBEC3-KT, Airway Epithelial Cell Basal Medium and Bronchial Epithelial Cell Growth Kit (ATCC); hTERT-HME1, Mammary Epithelial Cell Basal Medium BulletKitTM without GA-1000 (Lonza); hTCEpi, KGMTM-2 BulletKitTM (Lonza).

All cell lines were cultured at 37 °C in a humidified atmosphere with 5% CO₂ and 95% air.

2.2. Animals

The animal experiment for the establishment of anti-PDPN mAbs was approved by the Animal Care and Use Committee of Tohoku University (approval no. 2016MdA-153). To investigate the ADCC and antitumor activity of PMab-117-mG_{2a}, animal experiments were approved by the Institutional Committee for Experiments of the Institute of Microbial Chemistry (approval nos. 2024-062 [ADCC] and 2018-031 [antitumor activity]). Animals were maintained in a pathogen-free condition on 11 h light/13 h dark cycle with food and water supplied ad libitum. The health and weight were monitored every one or five days. We identified body weight loss exceeding 25% and maximum tumor size exceeding 3000 mm³ as humane endpoints.

2.3. Hybridoma Production

A five-week-old Sprague–Dawley rat (CLEA Japan, Tokyo, Japan) was immunized with LN229/PDPN (1×10^9 cells) together with Imject Alum (Thermo) via intraperitoneal injection. After three additional injections every week (1×10^9 cells/rat), a final booster injection (1×10^9 cells/rat) was performed two days before harvesting spleen cells. The hybridomas were produced, as described previously [40]. Culture supernatants were screened using enzyme-linked immunosorbent assay (ELISA) for binding to PDPN ectodomain (PDPNec). The higher reactivity to cancer cell lines (PC-10 and LN319) than embryonic kidney 293FT cells using flow cytometry was critical for selecting CasMabs.

2.4. ELISA

PDPNec was immobilized on Nunc Maxisorp 96-well immunoplates (Thermo) at 1 $\mu\text{g}/\text{mL}$ for 30 min. After blocking with 1% bovine serum albumin (BSA) in 0.05% Tween 20-phosphate-buffered saline (PBS, Nacalai), the plates were incubated with culture supernatant followed by 1:20000 diluted peroxidase-conjugated anti-rat immunoglobulins (Sigma). The enzymatic reaction was produced with an ELISA POD Substrate TMB Kit (Nacalai). The optical density was measured at 655 nm using an iMark microplate reader (Bio-Rad Laboratories, Inc., Berkeley, CA, USA).

2.5. Antibodies

For the generation of PMab-117-mG_{2a}, the complementarity determining region (CDR) of PMab-117 V_H, frame sequences of V_H in mouse IgG_{2a}, and C_H of mouse IgG_{2a} were cloned into the pCAG-Neo vector [FUJIFILM Wako Pure Chemical Corporation (Wako), Osaka, Japan]. The CDR of PMab-117 V_L, frame sequences of V_L in mouse Ig, and C_L of the mouse kappa chain were cloned into the pCAG-Ble vector (Wako). We transfected the PMab-117-mG_{2a} expression vectors into BINDS-09 cells using the ExpiCHO-S Expression System (Thermo). We purified PMab-117-mG_{2a} using Ab-Capcher (ProteNova Co., Ltd., Kagawa, Japan). NZ-1 (an anti-PDPN mAb) [43] and PMab-231 (control mouse IgG_{2a}) [44] were previously described. Mouse IgG (mIgG) was purchased from Wako.

2.6. Flow cytometry

Cells were collected using 0.25% trypsin and 1 mM ethylenediamine tetraacetic acid (EDTA; Nacalai). The cells (1×10^5 cells/sample) were treated with NZ-1, PMab-117, PMab-117-mG_{2a}, or blocking buffer (control) (0.1% BSA in PBS) for 30 min at 4 °C. Next, the cells were treated with Alexa Fluor 488-conjugated anti-rat or mouse IgG (1:1000; Cell Signaling Technology, Danvers, MA, USA) for 30 min at 4 °C. The SA3800 Cell Analyzer (Sony Corp., Tokyo, Japan) was used to collect the fluorescence data, which were analyzed using FlowJo software (BD Biosciences, Franklin Lakes, NJ, USA).

2.7. Determination of the Binding Affinity by Flow Cytometry

After being suspended in 100 μ L of serially diluted PMab-117-mG_{2a} or NZ-1, the cells were then incubated with Alexa Fluor 488-conjugated anti-mouse or rat IgG (1:200), respectively. The SA3800 Cell Analyzer was used to obtain the fluorescence data. To calculate the dissociation constant (K_D), GraphPad PRISM 6 software (GraphPad Software, Inc., La Jolla, CA, USA) was used.

2.8. ADCC

Effector splenocytes were obtained from the spleen of female BALB/c nude mice (Jackson Laboratory Japan, Inc., Kanagawa, Japan) as described previously [45]. CHO/PDPN, PC-10, and LN319 cells were labeled with 10 μ g/mL of Calcein AM (Thermo). Target cells (1×10^4 cells/well) were plated and mixed with the effector cells (effector-to-target ratio, 50: 1) and 100 μ g/mL of control mouse IgG_{2a} (PMab-231) or PMab-117-mG_{2a}. The released calcein into the medium was measured after a 4.5 h incubation. Fluorescence intensity was determined using a microplate reader (Power Scan HT; BioTek Instruments, Winooski, VT, USA) with excitation and emission wavelengths of 485 and 538 nm, respectively. After lysing all cells with a buffer containing 0.5% Triton X-100, 10 mM Tris-HCl (pH 7.4), and 10 mM EDTA, cytotoxicity (% lysis) was calculated as % lysis = $(E - S)/(M - S) \times 100$, where E is the fluorescence of the combined target and effector cells, S is the spontaneous fluorescence of target cells only, and M is the maximum fluorescence measured.

2.9. Antitumor Activity of PMab-117-mG_{2a} in Xenografts of LN229/PDPN, PC-10, and LN319

LN229/PDPN, PC-10, or LN319 was suspended in 0.3 mL of DMEM (1.33×10^8 cells/mL) and mixed with 0.5 mL of BD Matrigel Matrix Growth Factor Reduced (BD Biosciences). Then, BALB/c nude mice (Jackson Laboratory Japan, Kanagawa, Japan) were injected subcutaneously in the left flank with 100 μ L of the suspension (5×10^6 cells). Following the inoculation of LN229/PDPN, PC-10, or LN319 (day 0), PMab-117-mG_{2a} (n = 8) or control mIgG (n = 8) was intraperitoneally injected into the xenograft-bearing mice on days 1, 8, and 16 (LN229/PDPN and LN319) or days 1, 8, 14, and 22 (PC-10). The tumor volume was calculated using the following formula: volume = $W^2 \times L/2$, where W is the short diameter and L is the long diameter. All mice were euthanized by cervical dislocation 22~30 days after cell inoculation.

2.10. Statistical Analyses

All data are represented as the mean \pm standard error of the mean (SEM). Two-tailed unpaired t test was used for the statistical analyses of ADCC and tumor weight. Two-way ANOVA and Sidak's multiple comparisons test was used for tumor volume and mouse weight. $p < 0.05$ was considered to indicate a statistically significant difference.

3. Results

3.1. Production and Screening of an Anti-PDPN CasMab, PMab-117

We immunized a rat with LN229/PDPN cells. The culture supernatants of hybridomas were screened using ELISA with PDPNec. We further screened the reactivity to PDPN-positive cancer cell lines (PC-10 and LN319) and embryonic kidney 293FT cells using flow cytometry (Figure 1A). One of the established hybridomas, PMab-117 (IgM, kappa) reacted with LN229/PDPN, PC-10, and LN319, but not with PDPN-negative LN229 and PDPN-knockout LN319 (BINDS-55) (Figure 1B). NZ-1, an anti-PDPN mAb (rat IgG_{2a}), showed a higher reactivity to those cancer cell lines (Figure 1B). Next, we compared the reactivity of PMab-117 and NZ-1 to 293FT and PODO/TERT256 (TERT-expressed

normal kidney podocyte). As shown in Figure 1C, PMAb-117 exhibited a low and no reactivity to 293FT and PODO/TERT256, respectively. In contrast, NZ-1 showed the reactivity to both 293FT and PODO/TERT256 (Figure 1C).




Figure 1. Selection of anti-PDPN CasMab, PMAb-117. (A) A scheme of CasMab selection from anti-PDPN mAb-producing hybridoma clones. (B) Flow cytometry using PMAb-117 (10 $\mu\text{g}/\text{mL}$; Red line), NZ-1 (10 $\mu\text{g}/\text{mL}$; Red line) or buffer control (Black line) against LN229, LN229/PDPN, PC-10, LN319, and PDPN-knockout LN319 (BINDS-55). (C) Flow cytometry using PMAb-117 (10 $\mu\text{g}/\text{mL}$; Red line), NZ-1 (10 $\mu\text{g}/\text{mL}$; Red line), or buffer control (Black line) against 293FT (human embryonic kidney) and PODO/TERT256 (TERT-expressed normal kidney podocyte).

3.2. Production of PMAb-117-mG_{2a} and the Reactivity to Cancer Cells, Normal Kidney Podocytes, and Epithelial Cells

Since PMAb-117 is an IgM mAb, it is somewhat problematic to compare the reactivity to IgG mAbs, including NZ-1. Furthermore, evaluating *in vivo* antitumor activity in mouse xenograft models is difficult. Therefore, we produced a class-switched mouse IgG_{2a} mAb (PMAb-117-mG_{2a}) from PMAb-117. We cloned the V_H cDNA of PMAb-117 and combined it with the C_H cDNA of mouse IgG_{2a}. We also cloned the V_L cDNA of PMAb-117 and combined it with the C_L cDNA of the mouse kappa light chain. Finally, PMAb-117-mG_{2a} was produced using Fut8-deficient ExpiCHO-S (BINDS-09) cells (Figure 2A). In reduced condition, we confirm the purity of original and recombinant mAbs by SDS-

PAGE (Supplementary Figure S1). As shown in Figure 2B, PMab-117-mG_{2a} reacted with LN229/PDPN, PC-10, and LN319 but not with LN229 and BINDS-55. NZ-1 showed a similar reactivity to those cancer cell lines (Figure 2B). We next compared the reactivity of PMab-117-mG_{2a} and NZ-1 to 293FT, PODO/TERT256, and TERT-expressed normal epithelial cells, including HBEC3-KT (lung bronchus), hTERT-HME1 (mammary gland), and hTCEpi (cornea). As shown in Figure 2C, PMab-117-mG_{2a} exhibited a low reactivity to 293FT. Furthermore, PMab-117-mG_{2a} did not show the reactivity to PODO/TERT256, HBEC3-KT, hTERT-HME1, and hTCEpi. In contrast, NZ-1 showed the reactivity to 293FT and those normal cells (Figure 2C).




Figure 2. Production of PMab-117-mG_{2a} and the reactivity to cancer cells, normal kidney podocytes, and epithelial cells. (A) Class-switched mouse IgG_{2a} mAb, PMab-117-mG_{2a}, was generated from PMab-117 (rat IgM). (B) Flow cytometry using PMab-117-mG_{2a} (1 μg/mL; Red line), NZ-1 (1 μg/mL; Red line) or buffer control (Black line) against LN229, LN229/PDPN, PC-10, LN319, and PDPN-knockout LN319 (BINDS-55). (C) Flow cytometry using PMab-117-mG_{2a} (1 μg/mL; Red line), NZ-1 (1 μg/mL; Red line) or buffer control (Black line) against 293FT (human embryonic kidney), PODO/TERT256 (kidney podocyte), HBEC3-KT (lung bronchus epithelial cell), hTERT-HME1 (mammary gland epithelial cell), and hTCEpi (corneal epithelial cell).

The K_D for the interaction of PMab-117-mG_{2a} and NZ-1 with LN319 was determined by flow cytometry. As shown in Figure 3, the K_D values for PMab-117-mG_{2a} and NZ-1 with LN319 were 1.9×10^{-7} M and 5.0×10^{-9} M, respectively.




Figure 3. Determination of the binding affinity of PMab-117-mG_{2a} and NZ-1 using flow cytometry. LN319 cells were suspended in PMab-117-mG_{2a} or NZ-1 at indicated concentrations, followed by treatment with anti-mouse or rat IgG conjugated with Alexa Fluor 488. The SA3800 Cell Analyzer was used to analyze fluorescence data. The dissociation constant (K_D) values were determined using GraphPad Prism 6.

These results indicated that PMab-117-mG_{2a} could recognize tumor cells but not normal kidney podocytes and epithelial cells from the lung bronchus, mammary gland, and cornea. In contrast, one of the non-CasMabs against PDPN, NZ-1, showed high reactivity to both tumor and normal epithelial cells.

3.3. ADCC by PMab-117-mG_{2a} against PDPN-Positive Cells

We then examined whether PMab-117-mG_{2a} possesses ADCC activity against PDPN-positive cells. As shown in Figure 4, PMab-117-mG_{2a} induced ADCC against LN229/PDPN cells (17.3% cytotoxicity; $p < 0.01$) more effectively than the control mouse IgG_{2a} (3.8% cytotoxicity). PMab-117-mG_{2a} also elicited more potent ADCC against endogenous PDPN expressing tumor PC-10 (42.1% cytotoxicity; $p < 0.01$) and LN319 (23.9% cytotoxicity; $p < 0.01$) cells. These results demonstrated that PMab-117-mG_{2a} exhibited potent ADCC activities against PDPN-positive cells.




Figure 4. The ADCC activity by PMab-117-mG_{2a} in PDPN-positive cells. The ADCC induced by PMab-117-mG_{2a} or control mouse IgG_{2a} (PMab-231) against LN229/PDPN (A), PC-10 (B), and LN319 (C) cells. Values are shown as the mean \pm SEM. Asterisks indicate statistical significance (** $p < 0.01$; two-tailed unpaired t-test).

3.4. Antitumor Effects of PMAb-117-mG_{2a} against PDPN-Positive Cells in Mouse Xenograft Models

Following the inoculation of LN229/PDPN, PC-10, or LN319 (day 0), PMAb-117-mG_{2a} or control mIgG was intraperitoneally injected into the xenograft-bearing mice on days 1, 8, and 16 (LN229/PDPN and LN319) or days 1, 8, 14, and 22 (PC-10). The tumor volume was measured on the indicated days. The PMAb-117-mG_{2a} administration resulted in a significant reduction in LN229/PDPN xenografts on days 16 ($p < 0.01$), 27 ($p < 0.01$), and 30 ($p < 0.01$) compared with that of control mIgG (Figure 5A). A significant reduction was observed in the PC-10 xenograft on days 22 ($p < 0.01$), 26 ($p < 0.01$), and 28 ($p < 0.01$) (Figure 5B). A significant reduction was also observed in the LN319 xenograft on days 19 ($p < 0.01$) and 22 ($p < 0.01$) (Figure 5C).




Figure 5. Antitumor activity of PMAb-117-mG_{2a} against human tumor xenografts. (A–C) LN229/PDPN (A), PC-10 (B), and LN319 (C) cells were subcutaneously injected into BALB/c nude mice (day 0). PMAb-117-mG_{2a} (100 μ g) or control mouse IgG (mIgG, 100 μ g) were intraperitoneally injected into each mouse on days 1, 8, and 16 (LN229/PDPN and LN319, arrows) or days 1, 8, 14, and 22 (PC-10, arrows). The tumor volume is represented as the mean \pm SEM. ** $p < 0.01$ (two-way ANOVA and Sidak's multiple comparisons test). (D–F) The mice were euthanized on day 30 (LN229/PDPN), day 28 (PC-10), or day 22 (LN319) after cell inoculation. The tumor weights of LN229/PDPN (D), PC-10 (E), and LN319 (F) xenografts were measured. Values are presented as the mean \pm SEM. ** $p < 0.01$, (two-tailed unpaired t-test). (G–I) LN229/PDPN (G), PC-10 (H), and LN319 (I) xenograft tumors (scale bar, 1 cm). (J–L) Body weights of LN229/PDPN (J), PC-10 (K), and LN319 (L) xenograft-bearing mice treated with control mIgG or PMAb-117-mG_{2a}.

A significant reduction in xenograft weight caused by PMab-117-mG_{2a} was observed in LN229/PDPN (64% reduction; $p < 0.01$; Figure 5D), PC-10 (55% reduction; $p < 0.01$; Figure 5E), and LN319 (48% reduction; $p < 0.01$; Figure 5F). The LN229/PDPN, PC-10, and LN319 xenografts were resected from mice on days 30, 28, and 22, respectively (Figure 5G–I) respectively

The xenograft-bearing mice did not lose body weight (Figure 5J–L). The mice on day 30 (LN229/PDPN), day 28 (PC-10), and day 22 (LN319) are shown in Supplementary Figure S2.

4. Discussion

For the development of mAbs for tumor therapy, the identification and validation of adequate antigenic targets are important [1]. To achieve an acceptable therapeutic index and avoid on-target toxicity, target antigens should ideally have high tumor expression levels and little or no expression in normal tissues. However, the limitation of the ideal target antigens is a severe problem. Some technologies, including bispecific antibodies, defucosylated antibodies, and ADCs, enhance the activity of antibodies, contributing to tumor therapy development. However, on-target toxicity due to recognizing antigens in normal cells has not been resolved. Therefore, selecting mAb that recognizes cancer-specific epitopes is essential to reduce the adverse effects. This study developed a novel CasMab against PDPN (PMab-117) by immunizing LN229/PDPN with a rat (Figure 1). The mouse IgG_{2a} type PMab-117 (PMab-117-mG_{2a}) reacted with the PDPN-positive tumor cells but not with normal kidney podocytes and normal epithelial cells from lung bronchus, mammary gland, and corneal (Figure 2). Furthermore, PMab-117-mG_{2a} exerted a potent ADCC (Figure 4) and antitumor effect in PC-10 and LN319 xenografts (Figure 5).

The reactivity of PMab-117-mG_{2a} in flow cytometry is low in PC-10 (Figure 2B). In contrast, PMab-117-mG_{2a} exhibited high ADCC activity (Figure 4) and antitumor effect (Figure 5). Although the target cell-derived immunosuppressive factors such as PD-L1 or TGF- β would contribute to the responses, the reactivity of PMab-117-mG_{2a} in PC-10 is sufficient to exert ADCC and antitumor efficacy *in vivo*. In this condition, PMab-117-mG_{2a} did not react with normal kidney podocytes, lung bronchus epithelial cells, mammary gland epithelial cells, and corneal epithelial cells (Figure 2C). We should investigate the *in vivo* side effects in the future. Human PDPN PLAG4 domain knock-in mice were generated [46]. Since PMab-117-mG_{2a} possesses the epitope around the PLAG4 domain (see below), it is worthwhile to evaluate the side effect *in vivo* if PMab-117-mG_{2a} can recognize the human/mouse chimeric PDPN. Furthermore, evaluating the humanized PMab-117-mG_{2a} to apply clinical studies is essential. We should assess not only the antitumor efficacy but also toxicity to normal tissues using cynomolgus monkeys [40].

We have reported CasMabs against PDPN (LpMab-2 [39] and LpMab-23 [40]), which were obtained by immunization of LN229/PDPN with mice. LpMab-2 recognizes a glycopeptide (Thr55-Leu64) structure of PDPN [39]. LpMab-23 recognizes a naked peptide structure of PDPN (Gly54–Leu64), especially Gly54, Thr55, Ser56, Glu57, Asp58, Arg59, Tyr60, and Leu64 of PDPN is a critical epitope of LpMab-23 [47]. PMab-117, obtained by immunization of LN229/PDPN with a rat, recognizes the glycopeptide structure of PDPN (Ile78–Thr85) around PLAG4 domain, which includes O-glycosylated Thr85 [14]. A mAb with the specificity and epitope of PMab-117 has never been obtained by immunization with mice. Therefore, the strategies for CasMab generation using mouse or rat immunization can contribute to developing novel CasMabs against various tumor antigens.

Chimeric antigen receptor (CAR)-T cell therapy against solid tumors has been evaluated in clinical trials [48]. Our established anti-PDPN mAbs, NZ-1 and LpMab-2, were developed for CAR-T cell therapy and evaluated in pre-clinical studies. Systemic injection of an NZ-1-based CAR-T cells inhibited the intracranial glioma growth in immunodeficient mice [49]. A LpMab-2-based CAR-T cell killed patient-derived glioma stem cells and also inhibited the growth of a glioma xenograft in immunodeficient mice [50]. Therefore, CAR-T cell therapy that targets PDPN would be a promising immunotherapy for the treatment of GBM [51]. We should investigate the cancer-specific reactivity of PMab-117 single-chain Fv and apply it to CAR-T cell therapy.

Our developed CasMabs against HER2 (clones H₂Mab-214 [52] and H₂Mab-250 [53]) were also screened by the reactivity to cancer and normal cells in flow cytometry. Both CasMabs exhibited the antitumor effect in mouse xenograft models using their recombinant mouse IgG_{2a} or human IgG₁ mAbs [44,54]. H₂Mab-250 has been developed as CAR-T-cell therapy. The phase I study has been conducted in the US (NCT06241456). Furthermore, the recognition mode of H₂Mab-214 was solved by X-ray

crystallography. H₂Mab-214 recognizes a locally misfolded structure of HER2 extracellular domain 4, which usually forms a β -sheet [52]. The structural analysis of the PMab-117-PDPN complex is also essential to reveal the mechanism of cancer-specific recognition.

As shown in Figure 3, PMab-117-mG_{2a} possesses ~40-fold lower affinity (K_D : 1.9×10^{-7} M) than NZ-1 (K_D : 5.0×10^{-9} M). The K_D values of other CasMabs against PDPN (LpMab-2 and LpMab-23) were previously determined as 5.7×10^{-9} M and 1.2×10^{-8} M, respectively [39,47]. These CasMabs have different binding affinity from 10^{-7} M to 10^{-9} M order. Recently, CAR's affinity to antigen determines CAR-T therapy's efficacy and persistence. Trogocytosis was first proposed as a mechanism of immune escape to CAR-T therapy against CD19 [55]. When CD19-positive lymphoma cells are co-cultured with CAR-T cells with the high-affinity anti-CD19 FMC63-based CAR, the CAR-T cells remove CD19 from lymphoma cells and acquire it on the plasma membrane [55]. The phenomenon is called "trogocytosis," which generates antigen-negative target cells. Furthermore, the CAR-T cells that incorporated CD19 by trogocytosis can be attacked by the other CAR-T cells [55]. To limit trogocytosis, the reduction of CAR affinity has been proposed. CD19-targeting CAR with ~40-fold lower affinity than the FMC63-based CAR showed higher efficacy and persistence than FMC63-based CAR-T in two clinical trials [56,57]. These results suggest that the reduction of CAR affinity limits trogocytosis and maintains antitumor activity as well as clinical efficacy. The property of anti-PDPN CasMabs could contribute to the future development of PDPN-targeting CAR-T cells by limiting trogocytosis and maintaining cancer specificity.

ADCs are one of the growing modalities for solid tumor therapy. However, safety issues are one of the reasons for the termination. Bivatuzumab–mertansine, a humanized anti-CD44v6 ADC, was developed and evaluated in clinical trials [58]. However, the clinical trials were terminated due to the severe skin toxicity. Since CD44v6 is expressed in the skin epidermis, the efficient accumulation of mertansine in the skin probably leads to skin disorders [58,59]. The strategy of CasMab selection may contribute to developing anti-CD44v6 CasMabs to reduce the adverse effects and overcome the depletion of target antigens for tumor therapy.

Supplementary Materials: The following supporting information can be downloaded at the website of this paper posted on Preprints.org, Figure S1: Confirmation of the purified mAbs; Figure S2: Body appearance in LN229/PDPN (A), PC-10 (B), and LN319 (C) xenografts-implanted mice.

Author Contributions: Conceptualization, M.K.K., and Y.K.; methodology, T.O.; formal analysis, T.T.; investigation, H.S., T.O., and T.T.; data curation, H.S. and Y.K.; writing—original draft preparation, H.S.; writing—review and editing, Y.K.; project administration, Y.K.; funding acquisition, H.S., T.T., M.K.K., and Y.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research was supported in part by the Japan Agency for Medical Research and Development (AMED) under Grant Numbers 24am0521010 (to Y.K.), JP23ama121008 (to Y.K.), JP23am0401013 (to Y.K.), JP23bm1123027 (to Y.K.), and JP23ck0106730 (to Y.K.), and by the Japan Society for the Promotion of Science (JSPS) Grants-in-Aid for Scientific Research (KAKENHI) grant nos. 22K06995 (to H.S.), 21K20789 (to T.T.), 21K07168 (to M.K.K.), and 22K07224 (to Y.K.).

Institutional Review Board Statement: The Animal Care and Use Committee of Tohoku University approved an animal experiment (approval no. 2016MdA-153). The Institutional Committee for Experiments of the Institute of Microbial Chemistry approved animal experiments (approval nos. 2024-062 [ADCC] and 2018-031 [antitumor activity]).

Informed Consent Statement: Not applicable.

Data Availability Statement: The data presented in this study are available in the article and supplementary material.

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Paul, S.; Konig, M.F.; Pardoll, D.M.; et al. Cancer therapy with antibodies. *Nat Rev Cancer* 2024;24(6): 399-426.
2. Leavy, O. Therapeutic antibodies: past, present and future. *Nat Rev Immunol* 2010;10(5): 297.
3. Oh, D.Y.; Bang, Y.J. HER2-targeted therapies - a role beyond breast cancer. *Nat Rev Clin Oncol* 2020;17(1): 33-48.

4. Blick, S.K.; Scott, L.J. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. *Drugs* 2007;67(17): 2585-2607.
5. Tsao, L.C.; Force, J.; Hartman, Z.C. Mechanisms of Therapeutic Antitumor Monoclonal Antibodies. *Cancer Res* 2021;81(18): 4641-4651.
6. Dumontet, C.; Reichert, J.M.; Senter, P.D.; Lambert, J.M.; Beck, A. Antibody-drug conjugates come of age in oncology. *Nat Rev Drug Discov* 2023;22(8): 641-661.
7. Beck, A.; Goetsch, L.; Dumontet, C.; Corvaia, N. Strategies and challenges for the next generation of antibody-drug conjugates. *Nat Rev Drug Discov* 2017;16(5): 315-337.
8. Hurvitz, S.A.; Dirix, L.; Kocsis, J.; et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. *J Clin Oncol* 2013;31(9): 1157-1163.
9. Rosenberg, J.E.; O'Donnell, P.H.; Balar, A.V.; et al. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy. *J Clin Oncol* 2019;37(29): 2592-2600.
10. Wahby, S.; Fashoyin-Aje, L.; Osgood, C.L.; et al. FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer. *Clin Cancer Res* 2021;27(7): 1850-1854.
11. Modi, S.; Park, H.; Murthy, R.K.; et al. Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study. *J Clin Oncol* 2020;38(17): 1887-1896.
12. Coleman, R.L.; Lorusso, D.; Gennigens, C.; et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol* 2021;22(5): 609-619.
13. Moore, K.N.; Angelergues, A.; Konecny, G.E.; et al. Mirvetuximab Soravtansine in FR α -Positive, Platinum-Resistant Ovarian Cancer. *N Engl J Med* 2023;389(23): 2162-2174.
14. Suzuki, H.; Kaneko, M.K.; Kato, Y. Roles of Podoplanin in Malignant Progression of Tumor. *Cells* 2022;11(3).
15. Sekiguchi, T.; Takemoto, A.; Takagi, S.; et al. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. *Oncotarget* 2016;7(4): 3934-3946.
16. Kaneko, M.; Kato, Y.; Kunita, A.; et al. Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. *J Biol Chem* 2004;279(37): 38838-38843.
17. Braun, A.; Anders, H.J.; Guderhann, T.; Mammadova-Bach, E. Platelet-Cancer Interplay: Molecular Mechanisms and New Therapeutic Avenues. *Front Oncol* 2021;11: 665534.
18. Fujita, N.; Takagi, S. The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. *J Biochem* 2012;152(5): 407-413.
19. Takemoto, A.; Miyata, K.; Fujita, N. Platelet-activating factor podoplanin: from discovery to drug development. *Cancer Metastasis Rev* 2017;36(2): 225-234.
20. Krishnan, H.; Rayes, J.; Miyashita, T.; et al. Podoplanin: An emerging cancer biomarker and therapeutic target. *Cancer Sci* 2018;109(5): 1292-1299.
21. Li, K.; Guo, J.; Ming, Y.; et al. A circular RNA activated by TGF β promotes tumor metastasis through enhancing IGF2BP3-mediated PDPN mRNA stability. *Nat Commun* 2023;14(1): 6876.
22. de Winde, C.M.; George, S.L.; Crosas-Molist, E.; et al. Podoplanin drives dedifferentiation and amoeboid invasion of melanoma. *iScience* 2021;24(9): 102976.
23. Wicki, A.; Lehembre, F.; Wick, N.; et al. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. *Cancer Cell* 2006;9(4): 261-272.
24. Grass, G.D.; Tolliver, L.B.; Bratoeva, M.; Toole, B.P. CD147, CD44, and the epidermal growth factor receptor (EGFR) signaling pathway cooperate to regulate breast epithelial cell invasiveness. *J Biol Chem* 2013;288(36): 26089-26104.
25. Li, Y.Y.; Zhou, C.X.; Gao, Y. Podoplanin promotes the invasion of oral squamous cell carcinoma in coordination with MT1-MMP and Rho GTPases. *Am J Cancer Res* 2015;5(2): 514-529.
26. Zhao, P.; Xu, Y.; Wei, Y.; et al. The CD44s splice isoform is a central mediator for invadopodia activity. *J Cell Sci* 2016;129(7): 1355-1365.
27. Friedman, G.; Levi-Galibov, O.; David, E.; et al. Cancer-associated fibroblast compositions change with breast cancer progression linking the ratio of S100A4(+) and PDPN(+) CAFs to clinical outcome. *Nat Cancer* 2020;1(7): 692-708.
28. Hirayama, K.; Kono, H.; Nakata, Y.; et al. Expression of podoplanin in stromal fibroblasts plays a pivotal role in the prognosis of patients with pancreatic cancer. *Surg Today* 2018;48(1): 110-118.
29. Liu, X.; Cao, Y.; Lv, K.; et al. Tumor-infiltrating podoplanin(+) cells in gastric cancer: clinical outcomes and association with immune contexture. *Oncoimmunology* 2020;9(1): 1845038.
30. Wang, H.; Hu, C.; Song, X.; et al. Expression of Podoplanin in Sinonasal Squamous Cell Carcinoma and Its Clinical Significance. *Am J Rhinol Allergy* 2020;34(6): 800-809.

31. Shindo, K.; Aishima, S.; Ohuchida, K.; et al. Podoplanin expression in cancer-associated fibroblasts enhances tumor progression of invasive ductal carcinoma of the pancreas. *Mol Cancer* 2013;12(1): 168.
32. Pula, B.; Jethon, A.; Piotrowska, A.; et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. *Histopathology* 2011;59(6): 1249-1260.
33. Hoshino, A.; Ishii, G.; Ito, T.; et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. *Cancer Res* 2011;71(14): 4769-4779.
34. Sasaki, K.; Sugai, T.; Ishida, K.; et al. Analysis of cancer-associated fibroblasts and the epithelial-mesenchymal transition in cutaneous basal cell carcinoma, squamous cell carcinoma, and malignant melanoma. *Hum Pathol* 2018;79: 1-8.
35. Suzuki, J.; Aokage, K.; Neri, S.; et al. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. *Lung Cancer* 2021;153: 1-10.
36. Yoshida, T.; Ishii, G.; Goto, K.; et al. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. *Clin Cancer Res* 2015;21(3): 642-651.
37. Sakai, T.; Aokage, K.; Neri, S.; et al. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. *Lung Cancer* 2018;126: 64-71.
38. Rivas, E.I.; Linares, J.; Zwick, M.; et al. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+ breast tumors. *Nat Commun* 2022;13(1): 5310.
39. Kato, Y.; Kaneko, M.K. A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. *Sci Rep* 2014;4: 5924.
40. Yamada, S.; Ogasawara, S.; Kaneko, M.K.; Kato, Y. LpMab-23: A Cancer-Specific Monoclonal Antibody Against Human Podoplanin. *Monoclon Antib Immunodiagn Immunother* 2017;36(2): 72-76.
41. Suzuki, H.; Ohishi, T.; Kaneko, M.K.; Kato, Y. A Humanized and Defucosylated Antibody against Podoplanin (humLpMab-23-f) Exerts Antitumor Activities in Human Lung Cancer and Glioblastoma Xenograft Models. *Cancers (Basel)* 2023;15(20).
42. Kaneko, M.K.; Yamada, S.; Nakamura, T.; et al. Antitumor activity of chLpMab-2, a human-mouse chimeric cancer-specific antihuman podoplanin antibody, via antibody-dependent cellular cytotoxicity. *Cancer Med* 2017;6(4): 768-777.
43. Kato, Y.; Kaneko, M.K.; Kuno, A.; et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. *Biochem Biophys Res Commun* 2006;349(4): 1301-1307.
44. Kaneko, M.K.; Suzuki, H.; Ohishi, T.; et al. A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models. *Int J Mol Sci* 2024;25(3).
45. Li, G.; Suzuki, H.; Ohishi, T.; et al. Antitumor activities of a defucosylated anti-EpCAM monoclonal antibody in colorectal carcinoma xenograft models. *Int J Mol Med* 2023;51(2).
46. Ukaji, T.; Takemoto, A.; Shibata, H.; et al. Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents. *Cancer Sci* 2021;112(6): 2299-2313.
47. Kaneko, M.K.; Nakamura, T.; Kunita, A.; et al. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity. *Monoclon Antib Immunodiagn Immunother* 2017;36(3): 104-112.
48. Oliveira, G.; Wu, C.J. Dynamics and specificities of T cells in cancer immunotherapy. *Nat Rev Cancer* 2023;23(5): 295-316.
49. Shiina, S.; Ohno, M.; Ohka, F.; et al. CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains. *Cancer Immunol Res* 2016;4(3): 259-268.
50. Chalise, L.; Kato, A.; Ohno, M.; et al. Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma. *Mol Ther Oncolytics* 2022;26: 265-274.
51. Waseda, M.; Kaneko, S. Podoplanin as an Attractive Target of CAR T Cell Therapy. *Cells* 2020;9(9).
52. Arimori, T.; Mihara, E.; Suzuki, H.; et al. Locally misfolded HER2 expressed on cancer cells is a promising target for development of cancer-specific antibodies. *Structure* 2024.
53. Kaneko, M.K.; Suzuki, H.; Kato, Y. Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H(2)Mab-250/H(2)CasMab-2 for Breast Cancers. *Monoclon Antib Immunodiagn Immunother* 2024;43(2): 35-43.
54. Suzuki, H.; Ohishi, T.; Tanaka, T.; Kaneko, M.K.; Kato, Y. Anti-HER2 Cancer-Specific mAb, H(2)Mab-250-hG(1), Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. *Int J Mol Sci* 2024;25(15).
55. Hamieh, M.; Dobrin, A.; Cabriolu, A.; et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. *Nature* 2019;568(7750): 112-116.
56. Roddie, C.; Dias, J.; O'Reilly, M.A.; et al. Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. *J Clin Oncol* 2021;39(30): 3352-3363.

57. Ghorashian, S.; Kramer, A.M.; Onuoha, S.; et al. Enhanced CART cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. *Nat Med* 2019;25(9): 1408-1414.
58. Tijink, B.M.; Buter, J.; de Bree, R.; et al. A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. *Clin Cancer Res* 2006;12(20 Pt 1): 6064-6072.
59. Riechelmann, H.; Sauter, A.; Golze, W.; et al. Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. *Oral Oncol* 2008;44(9): 823-829.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.